Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial
Bastiaan T van Dijk(Leiden University Medical Center), P Müller(Leiden University Medical Center), Y. Koopman-Keemink(Juliana Kinderziekenhuis), Sytske Anne Bergstra(Leiden University Medical Center), Dieneke Schonenberg‐Meinema(Emma Kinderziekenhuis), J. Merlijn van den Berg(Boston Children's Hospital), Marion A. J. van Rossum(Reade), Daniëlle M.C. Brinkman, Cornelia F Allaart(Leiden University Medical Center), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), R. ten Cate(Leiden University)
Cited by 1
Related Papers
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis
|Annals of the Rheumatic Diseases|2008|217
Predictors of health‐related quality of life in children and adolescents with juvenile idiopathic arthritis: Results from a web‐based survey
|Arthritis Care & Research|2012|155